The global cholesterol testing services market is expected to reach USD 17.57 Billion by 2021 from an estimated value of USD 11.96 Billion in 2016, growing at a CAGR of 8% during the forecast period.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180941049
Major players in the cholesterol testing market include Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific (Luxembourg), Spectra Laboratories Inc. (U.S.), Unilabs (Switzerland), SYNLAB International GmbH (Germany), Bio-Reference Laboratories Inc. (U.S.), Clinical Reference Laboratory, Inc. (CRL) (U.S.), ACM Medical Laboratory (U.S.), and Adicon Clinical Laboratory (China).
The cholesterol testing market is driven by factors such as increasing incidence of cardiovascular diseases and obesity, physician preference of laboratory testing rather self-testing, government initiatives to improve quality of testing, and rapid growth in the geriatric population are propelling the growth of this market. However, rapidly growing home/self-testing and advent of noninvasive cholesterol testing methods are the major factors that may hinder growth of the market.
Target Audience/Stakeholders:
- Cholesterol Testing Service Providers
- Cholesterol Testing Kit Manufacturers
- Public and Private Physicians
- Healthcare Institutions (Medical Data Centers)
- Diagnostic & Clinical Laboratories
- Distributors and Suppliers of Cholesterol Testing Kits
- Health Insurance Companies/Payers
- Pharmaceutical Companies
Request for Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=180941049
In 2016, North America is expected to account for the largest share of the market followed by Europe, Asia, and RoW. One of the major factors contributing to this large share in North America is the rising geriatric population, which has expanded the addressable patient population base.
This change is expected to put the spotlight on preventive measures such as clinical diagnostics, especially cholesterol tests, to reduce adverse events caused by diseases such as stroke, diabetes, and cardiovascular disease (CVD). In North America, the U.S. is a major market for cholesterol testing service providers. The dominance of the U.S. in cholesterol testing services market is due to the increase in Clinical Laboratory Improvement Amendments (CLIA) waivers for certain diagnostic tests, including blood cholesterol.